Glutamate and dopamine in schizophrenia: An update for the 21st century

Journal of Psychopharmacology

Volumn 29, Issue 2, 2015, Pages 97-115

  Howes, Oliver ^a,b   McCutcheon, Rob ^a,b   Stone, James ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

aetiology; antipsychotic; D2; dopamine; glutamate; imaging; mechanisms; MR; NMDA; PET; psychosis; Schizophrenia; treatment

Indexed keywords

6 FLUORODOPA F 18; BITOPERTIN; DIZOCILPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; GLUTAMIC ACID; IOLOPRIDE I 123; KETAMINE; LAMOTRIGINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAXAGOLIDE; NEUROLEPTIC AGENT; NITROPRUSSIDE SODIUM; OLANZAPINE; PHENCYCLIDINE; PLACEBO; POMAGLUMETAD METHIONIL; RACLOPRIDE C 11; TOPIRAMATE;

AUTOPSY; BASAL GANGLION; CHRONIC DISEASE; COGNITION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; HIGH RISK PATIENT; HIPPOCAMPUS; HUMAN; NEGATIVE SYNDROME; NEUROIMAGING; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRESYNAPTIC INHIBITION; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; THALAMUS; TREATMENT RESPONSE; VENTROMEDIAL PREFRONTAL CORTEX; ANIMAL; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; GLUTAMIC ACID; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84922233431     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114563634     Document Type: Review

References (264)

1. Aalto S, Hirvonen J, Kajander J, et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl). 2002 ; 164: 401-406
2. Aalto S, Ihalainen J, Hirvonen J, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl). 2005 ; 182: 375-383
3. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry. 1998 ; 155: 761-767
4. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry. 2004 ; 55: 1001-1006
5. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002 ; 22: 3708-3719
6. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000 ; 97: 8104-8109
7. Abi-Dargham A, van de, Giessen E, Slifstein M, et al. Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry. 2009 ; 65: 1091-1093
8. Abi-Dargham A, Xu X, Thompson JL, et al. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: A PET study with [11C]NNC112. J Psychopharmacol. 2012 ; 26: 794-805
9. Allen P, Chaddock CA, Howes OD, et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr Bull. 2012a ; 38: 1040-1049
10. Allen P, Luigjes J, Howes OD, et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull. 2012b ; 38: 1268-1276
11. Aoyama N, Théberge J, Drost DJ, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011 ; 198: 448-456
12. Arnold A, Freeman H. Reserpine in hospitalized psychotics: A controlled study on chronically disturbed women. AMA Arch Neurol Psychiatry. 1956 ; 76: 281-285
13. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006 ; 98: 641-653
14. Balla A, Sershen H, Serra M, et al. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology. 2003 ; 28: 34-44
15. Barch DM, Ceaser A. Cognition in schizophrenia: Core psychological and neural mechanisms. Trends Cogn Sci. 2012 ; 16: 27-34
16. Baron JC, Martinot JL, Cambon H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl). 1989 ; 99: 463-472
17. Bartha R, al-Semaan YM, Williamson PC, et al. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry. 1999 ; 45: 1403-1411
18. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997 ; 54: 959-965
19. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007 ; 318: 1645-1647
20. Bertolino A, Breier A, Callicott JH, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology. 2000 ; 22: 125-132
21. Block W, Bayer TA, Tepest R, et al. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: A proton magnetic resonance spectroscopy study. Neurosci Lett. 2000 ; 289: 147-151
22. Bloemen OJN, de Koning MB, Gleich T, et al. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur Neuropsychopharmacol. 2013 ; 23: 126-132
23. Bloomfield MAP, Morgan CJA, Egerton A, et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry. 2014 ; 75: 470-478
24. Bobanovic M, Bird DC, Robertson HA, et al. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol. 2000 ;: 1005-1012
25. Bose S, Mackinnon T, Mehta MA, et al. The effect of ageing on grey and white matter reductions in schizophrenia. Schizophrenia Research. 2009 ; 112: 7-13
26. Breier A, Adler CM, Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse. 1998 ; 29: 142-147
27. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: Rewarding, aversive, and alerting. Neuron. 2010 ; 68: 815-834
28. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab. 1991 ; 11: 220-228
29. Brücke T, Roth J, Podreka I, et al. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet. 1992 ; 339: 497
30. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009 ; 35: 383-402
31. Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - Results from the CandleLyte study. Eur Neuropsychopharmacol. 2014 ;:
32. Bustillo JR, Chen H, Jones T, et al. Increased glutamine in patients undergoing long-term treatment for schizophrenia: A proton magnetic resonance spectroscopy study at 3 T. JAMA Psychiatry. 2014 ; 71: 265-272
33. Bustillo JR, Rowland LM, Mullins P, et al. 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010 ; 15: 629-636
34. Campden-Main B, Wegielski Z. The control of deviant behaviour in chronically disturbed psychotic patients by the oral administration of reserpine. Ann N Y Acad Sci. 1955 ; 61: 117-122
35. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957 ; 180: 1200
36. Carlsson A, Roos B, Wålinder J, et al. Further studies on the mechanism of antipsychotic action: Potentiation by ∼t-methyltyrosine of thioridazine effects in chronic schizophrenics. J Neural Transm. 1973 ; 132: 125-132
37. Catafau AM, Searle GE, Bullich S, et al. Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors. J Cereb Blood Flow Metab. 2010 ; 30: 985-993
38. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 ; 26: 1185-1193
39. Chen KC, Yang YK, Howes O, et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: A case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis. Schizophr Bull. 2013 ; 39: 378-386
40. Christie MJ, Bridge S, James LB, et al. Excitotoxin lesions suggest an aspartatergic projection from rat medial prefrontal cortex to ventral tegmental area. Brain Res. 1985 ; 333: 169-172
41. Ciliax B, Heilman C. The dopamine transporter: Immunochemical characterization and localization in brain. J Neurosci. 1995 ; 15: 1714-1723
42. Coyle J. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 ; 26: 365-384
43. Creese I, Burt D, Snyder S. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976 ; 192: 481-483
44. Dao-Castellana MH, Paillère-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 1997 ; 23: 167-174
45. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry. 1991 ; 148: 1474-1486
46. Dawson N, Xiao X, McDonald M, et al. Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks. Cereb Cortex. 2014 ; 24: 452-464
47. de la Fuente-Sandoval C, León-Ortiz P, Azcárraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry. 2013 ; 70: 1057-1066
48. de la Fuente-Sandoval C, León-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011 ; 36: 1781-1791
49. Deakin JFW, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008 ; 65: 154-164
50. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014 ; 75: e11 - e13
51. Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012 ; 169: 1203-1210
52. Deutsch SI, Rosse RB, Billingslea EN, et al. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol. 2002 ; 449: 121-125
53. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999 ; 51: 7-61
54. Dursun S, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry. 1999 ; 245: 372-373
55. Dursun SM, Deakin JFW. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case series outcome study. J Psychopharmacol. 2001 ; 15: 297-301
56. Egerton A, Brugger S, Raffin M, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012 ; 37: 2515-2521
57. Egerton A, Chaddock C a, Winton-Brown TT, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biol Psychiatry. 2013 ; 74: 106-112
58. Egerton A, Demjaha A, McGuire P, et al. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010a ; 50: 524-531
59. Egerton A, Hirani E, Ahmad R, et al. Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: Reproducibility in tracer characteristics and characterization of extrastriatal binding. Synapse. 2010b ; 64: 301-312
60. Egerton A, Reid L, McGregor S, et al. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology (Berl). 2008 ; 198: 37-49
61. Ekelund J, Slifstein M, Narendran R, et al. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol. 2007 ; 9: 117-125
62. Elkashef A, Doudet D, Bryant T. 6-18 F-DOPA PET study in patients with schizophrenia. Psychiatry Res Neuroimaging. 2000 ; 100: 1-11
63. Farde L, Wiesel FA, Jansson P, et al. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl). 1988 ; 94: 1-7
64. Featherstone RE, Liang Y, Saunders JA, et al. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis. 2012 ; 47: 338-346
65. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 336-339
66. Funk A, Rumbaugh G, Harotunianc V, et al. Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia. Neuroreport. 2009 ; 20: 1019-1022
67. Funk AJ, McCullumsmith RE, Haroutunian V, et al. Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology. 2012 ; 37: 896-905
68. Fusar-Poli P, Howes O, Valmaggia L, et al. "Truman" signs and vulnerability to psychosis. Br J Psychiatry. 2008 ; 193: 168
69. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis. Arch Gen Psychiatry. 2010 ; 67: 683-691
70. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry. 2011 ; 16: 67-75
71. Galiska B, Szulc A, Tarasów E, et al. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit. 2009 ; 15: CR82 - CR88
72. Garety PA, Kuipers E, Fowler D, et al. A cognitive model of the positive symptoms of psychosis. Psychol Med. 2001 ; 31: 189-195
73. Gibbs JW, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000 ; 41: S10 - S16
74. Goff D. Bitopertin: The good news and bad news. JAMA Psychiatry. 2014 ;:
75. Goto N, Yoshimura R, Kakeda S, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012 ; 8: 119-122
76. Goyer PF, Berridge MS, Morris ED, et al. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med. 1996 ; 37: 1122-1127
77. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience. 1991 ; 41: 1-24
78. Graff-Guerrero A, Mizrahi R, Agid O, et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: A clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology. 2009 ; 34: 1078-1086
79. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 ; 21: 718-779
80. Hallak JEC, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013 ; 70: 668-676
81. Hammond J, Shan D, Meador-Woodruff J, et al Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders. Popoli M Diamond D Sanacora G, ed. New York: Springer, pp ; 2014: 265-294.
82. Harris LW, Sharp T, Gartlon J, et al. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci. 2003 ; 18: 1706-1710
83. Harrison PJ. The hippocampus in schizophrenia: A review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl). 2004 ; 174: 151-162
84. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005 ; 10: 40-68
85. Heckers S, Rauch SL, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci. 1998 ; 1: 318-323
86. Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: Salience attribution revisited. Schizophr Bull. 2010 ; 36: 472-485
87. Hietala J, Syvälahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 1999 ; 35: 41-50
88. Hietala J, Syvälahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 1995 ; 346: 1130-1131
89. Hirvonen J, van Erp TGM, Huttunen J, et al. Brain dopamine D1 receptors in twins discordant for schizophrenia. Am J Psychiatry. 2006 ; 163: 1747-1753
90. Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am J Psychiatry. 1998 ; 155: 1196-1201
91. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007 ; 27: 11496-11500
92. Horvath S, Mirnics K. Schizophrenia as a disorder of molecular pathways. Biol Psychiatry. 2014 ;:
93. Hosák L, Libiger J. Antiepileptic drugs in schizophrenia: A review. Eur Psychiatry. 2002 ; 17: 371-378
94. Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Mol Psychiatry. 2011a ; 16: 885-886
95. Howes O, Bose S, Turkheimer FE, et al. Dopamine synthesis capacity before onset of psychosis: A prospective -DOPA PET imaging study. Am J Psychiatry. 2011b ; 168: 1311-1317
96. Howes O, Egerton A, Allan V. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Curr Pharm Des. 2009a ; 15: 2550-2559
97. Howes O, Fusar-Poli P, Bloomfield MAP, et al. From the prodrome to chronic schizophrenia: The neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des. 2012a ; 18: 459-465
98. Howes OD, Gee S, McGuire PK, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic presccribing before clozapine initiation. Br J Psych. 2012b ; 201: 481-485
99. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012c ; 69: 776-786
100. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III - the final common pathway. Schizophr Bull. 2009 ; 35: 549-562
101. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psych. 2014 ; 205: 1-3
102. Howes OD, Montgomery AJ, Asselin M-C, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009b ; 66: 13-20
103. Howes O, Murray R. Schizophrenia: An integrated sociodevelopmental-cognitive model. Lancet. 2014 ; 6736: 1-11
104. Howes OD, Shotbolt P, Bloomfield M, et al. Dopaminergic function in the psychosis spectrum: An [18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophr Bull. 2013b ; 39: 807-814
105. Howes O, Williams M, Ibrahim K, et al. Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study. Brain. 2013a ; 136: 3242-3251
106. Humphries C, Mortimer A, Hirsch S, et al. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport. 1996 ; 7: 2051-2055
107. Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry. 2008 ; 63: 114-117
108. Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000 ; 250: 274-285
109. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992 ; 20: 1-97
110. Jackson ME, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A. 2004 ; 101: 8467-8472
111. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 ; 148: 1301-1308
112. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010 ; 47: 4-16
113. Javitt DC. Glutamate and schizophrenia: Phencyclidine, n-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007 ; 78: 69-108
114. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006 ; 29: 409-416
115. Kaalund SS, Newburn EN, Ye T, et al. Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. Mol Psychiatry. 2014 ; 19: 1258-1266
116. Kambeitz J, Abi-Dargham A, Kapur S, et al. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014 ; 204: 420-429
117. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003 ; 160: 13-23
118. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 2002 ; 7: 837-844
119. Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology. 1996 ; 15: 562-566
120. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 ; 157: 514-520
121. Karlsson P, Farde L, Halldin C, et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry. 2002 ; 159: 761-767
122. Kegeles LS, Abi-Dargham a, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry. 2000a ; 48: 627-640
123. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010 ; 67: 231-239
124. Kegeles LS, Martinez D, Kochan LD, et al. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse. 2002 ; 43: 19-29
125. Kegeles LS, Shungu DC, Anjilvel S, et al. Hippocampal pathology in schizophrenia: Magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 2000b ; 98: 163-175
126. Keshavan MS, Dick RM, Diwadkar Va, et al. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study. Schizophr Res. 2009 ; 115: 88-93
127. Kew JNC, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005 ; 179: 4-29
128. Kim E, Howes OD, Kapur S. Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci. 2013a ; 15: 315-328
129. Kim E, Howes OD, Turkheimer FE, et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A dual [(11)C]raclopride and [(18)F]FDG imaging study with aripiprazole. Psychopharmacology (Berl). 2013b ; 227: 221-229
130. Kim JS, Kornhuber HH, Schmid-Burgk W, et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980 ; 20: 379-382
131. Kim S, Lee H, Kim H-J, et al. In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia. NMR Biomed. 2011 ; 24: 1235-1242
132. Kinon BJ, Zhang L, Williams JE, et al. LY2140023 monohydrate: An agonist at the MLGU2/3 receptor for the treatment of schizophrenia. Schizophr Res. 2010 ; 117: 379-379
133. Kintzinger H, Arnold DG. A preliminary study of the effects of glutamic acid on catatonic schizophrenics. Rorschach Res Exch J Proj Tech. 1949 ; 13: 210-218
134. Klemm E, Grünwald F, Kasper S, et al. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry. 1996 ; 153: 183-190
135. Knol RJJ, de Bruin K, van Eck-Smit BLF, et al. In vivo [(123)I]CNS-1261 binding to D-serine-activated and MK801-blocked NMDA receptors: A storage phosphor imaging study in rats. Synapse. 2009 ; 63: 557-564
136. Korpi ER, Kaufmann CA, Marnela KM, et al. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 1987 ; 20: 337-345
137. Kosaka J, Takahashi H, Ito H, et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci. 2010 ; 86: 814-818
138. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994 ; 51: 199-214
139. Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches. Neuroscientist. 2009 ; 15: 635-650
140. Kumakura Y, Cumming P, Vernaleken I, et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa/positron emission tomography study. J Neurosci. 2007 ; 27: 8080-8087
141. Laruelle M. Schizophrenia: From dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014 ; 14C: 97-102
142. Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry. 1999 ; 46: 56-72
143. Levkovitz Y, Levi U, Braw Y, et al. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007 ; 1154: 154-162
144. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 ; 71: 138-149
145. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull. 1990 ; 16: 97-110
146. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987 ; 91: 415-433
147. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β- 11 C) DOPA and PET. Biol Psychiatry. 1999 ; 46: 681-688
148. Liu F, Guo X, Wu R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial. Schizophr Res. 2014 ; 153: 169-176
149. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology. 2006 ; 31: 1356-1361
150. Lutkenhoff ES, van Erp TG, Thomas MA, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010 ; 15: 308-318
151. Mackay AV, Iversen LL, Rossor M, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry. 1982 ; 39: 991-997
152. Majo VJ, Prabhakaran J, Mann JJ, et al. PET and SPECT tracers for glutamate receptors. Drug Discov Today. 2013 ; 18: 173-184
153. Malaspina D, Harkavy-Friedman J, Corcoran C, et al. Resting neural activity distinguishes subgroups of schizophrenia patients. Biol Psychiatry. 2004 ; 56: 931-937
154. Malmberg A, Jackson DM, Eriksson A, et al. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol. 1993 ; 43: 749-754
155. Manzoni O, Prezeau L, Desagher S, et al. Sodium nitroprusside blocks NMDA receptors via formation of ferrocyanide ions. Neuroreport. 1992 ; 3: 77-80
156. Marsman A, van den Heuvel MP, Klomp DWJ, et al. Glutamate in schizophrenia: A focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013 ; 39: 120-129
157. Mason G, Petersen K, de Graaf RA, et al. Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13 C] and [2-13C] glucose. J Neurochem. 2007 ; 100: 73-86
158. Matthysse S. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia?. Fed Proc. 1973 ; 32: 200-205
159. McCullumsmith R, Hammond J, Funk A, et al. Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. Curr Pharm Biotechnol. 2012 ; 13: 1535-1542
160. McGinnity CJ, Hammers A, Riaño Barros DA, et al. Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors. J Nucl Med. 2014 ; 55: 423-430
161. McGowan S, Lawrence AD, Sales T. Presynaptic dopaminergic dysfunction in schizophrenia. Arch Gen Psychiatry. 2004 ; 61: 134-142
162. McGuire P, Howes OD, Stone J, et al. Functional neuroimaging in schizophrenia: Diagnosis and drug discovery. Trends Pharmacol Sci. 2008 ; 29: 91-98
163. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002 ; 5: 267-271
164. Miller DW, Abercrombie ED. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull. 1996 ; 40: 57-62
165. Miyake N, Skinbjerg M, Easwaramoorthy B, et al. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol Psychiatry. 2011 ; 69: 822-824
166. Miyaoka T, Yasukawa R, Yasuda H, et al. Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol. 2008 ; 31: 287-292
167. Mizrahi R, Addington J, Rusjan PM, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 2012 ; 71: 561-567
168. Mizrahi R, Kenk M, Suridjan I, et al. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology. 2013 ; 39: 1479-1489
169. Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997 ; 17: 2921-2927
170. Monte AS, de Souza GC, McIntyre RS, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013 ; 27: 1032-1043
171. Morgan CJA, Curran HV. Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology (Berl). 2006 ; 188: 408-424
172. Morgan CJA, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: A comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction. 2009 ; 104: 77-87
173. Mortimer A, Singh P, Shepherd C, et al. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010 ; 4: 49-55
174. Murphy BP, Chung Y-C, Park T-W, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res. 2006 ; 88: 5-25
175. Murray AM, Hyde TM, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci. 1995 ; 15: 2186-2191
176. Narendran R, Frankle WG, Mason NS, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse. 2009 ; 63: 447-461
177. Narendran R, Jedema HP, Lopresti BJ, et al. Imaging dopamine transmission in the frontal cortex: A simultaneous microdialysis and [11C]FLB 457 PET study. Mol Psychiatry. 2014 ; 19: 302-310
178. Natsubori T, Inoue H, Abe O, et al. Reduced frontal glutamate + glutamine and n-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr Bull. 2014 ; 40: 1128-1139
179. Nielsen MØ, Rostrup E, Wulff S, et al. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry. 2012 ; 71: 898-905
180. Nordström AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl). 1992 ; 106: 433-438
181. Nordström AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993 ; 33: 227-235
182. Nozaki S, Kato M, Takano H, et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res. 2009 ; 108: 78-84
183. Ohrmann P, Siegmund A, Suslow T, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: A proton magnetic resonance spectroscopy study. Schizophr Res. 2005 ; 73: 153-157
184. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997 ; 385: 634-636
185. Olbrich HM, Valerius G, Rüsch N, et al. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry. 2008 ; 9: 59-63
186. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 ; 52: 998-1007
187. Ongur D, Prescot AP, Jensen JE, et al. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res - Neuroimaging. 2009 ; 172: 44-48
188. Owen F, Crow T, Poulter M, et al. Increased dopamine-receptor sensitivity in schizophrenia. Lancet. 1978 ; 312: 29-32
189. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med. 2007 ; 13: 1102-1107
190. Pearce R, Seeman P. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur Neurol. 1990 ; 30: 9-14
191. Perreault ML, Hasbi A, Alijaniaram M, et al. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: Increased high affinity state following amphetamine and in schizophrenia. J Biol Chem. 2010 ; 285: 36625-36634
192. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 1982 ; 28: 81-85
193. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry. 2006 ; 11: 118-119
194. Pilowsky LS, Costa DC, Ell PJ, et al. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: A 123I IBZM SPET (single photon emission tomography) study. Psychol Med. 1993 ; 23: 791-797
195. Pitcher G, Kalia L, Ng D, et al. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med. 2011 ; 17: 470-478
196. Poels EMP, Kegeles LS, Kantrowitz JT, et al. Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophr Res. 2014 ; 152: 325-332
197. Pogarell O, Koch W, Karch S, et al. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry. 2012 ; 45: S36 - S41
198. Purdon SE, Valiakalayil A, Hanstock CC, et al. Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophrenia Res. 2008 ; 99: 218-224
199. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A. 1994 ; 91: 11651-11654
200. Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia. J Clin Pharmacol. 2012 ; 32: 95-99
201. Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia?. J Neurochem. 1994 ; 63: 1576-1577
202. Roiser JP, Howes OD, Chaddock CA, et al. Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. Schizophr Bull. 2013 ; 39: 1328-1336
203. Roiser JP, Stephan KE, den Ouden HEM, et al. Do patients with schizophrenia exhibit aberrant salience?. Psychol Med. 2009 ; 39: 199-209
204. Rosenheck R, Leslie D, Keefe R, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006 ; 163: 411-417
205. Rotaru DC, Lewis DA, Gonzalez-Burgos G. The role of glutamatergic inputs onto parvalbumin-positive interneurons: Relevance for schizophrenia. Rev Neurosci. 2012 ; 23: 97-109
206. Rothman DL, Behar KL, Hyder F, et al. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: Implications for brain function. Annu Rev Physiol. 2003 ; 65: 401-427
207. Rowland LM, Spieker EA, Francis A, et al. White matter alterations in deficit schizophrenia. Neuropsychopharmacology. 2009 ; 34: 1514-1522
208. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005 ; 2: e141
209. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 ; 511: 421-427
210. Schlagenhauf F, Sterzer P, Schmack K, et al. Reward feedback alterations in unmedicated schizophrenia patients: Relevance for delusions. Biol Psychiatry. 2009 ; 65: 1032-1039
211. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013 ; 78: 81-93
212. Seeman P. Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse. 2012 ; 66: 88-93
213. Seeman P, Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975 ; 188: 1217-1219
214. Seeman P, Guan H, Van Tol H. Dopamine d4 receptors elevated in schizophrenia. Nature. 1993 ; 365: 441-445
215. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 ; 261: 717-719
216. Seeman P, Niznik HB, Guan HC, et al. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci U S A. 1989 ; 86: 10156-10160
217. Seeman P, Schwarz J, Chen J-F, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse. 2006 ; 60: 319-346
218. Selvaraj S, Arnone D, Cappai A, et al. Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014 ; 45C: 233-245
219. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol. 1992 ; 320: 145-160
220. Sharp FR, Tomitaka M, Bernaudin M, et al. Psychosis: Pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 2001 ; 24: 330-334
221. Shotbolt P, Stokes PR, Owens SF, et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med. 2011 ; 41: 2331-2338
222. Silvestri S, Seeman MV, Negrete J-C, et al. Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl). 2000 ; 152: 174-180
223. Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron. 2010 ; 65: 585-596
224. Smith GS, Schloesser R, Brodie JD, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology. 1998 ; 18: 18-25
225. Snyder SH. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am J Psychiatry. 1976 ; 133: 197-202
226. Sokolov BP. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J Neurochem. 1998 ; 71: 2454-2464
227. Soliman A, O'Driscoll GA, Pruessner J, et al. Stress-induced dopamine release in humans at risk of psychosis: A [11C]raclopride PET study. Neuropsychopharmacology. 2008 ; 33: 2033-2041
228. Sorce S, Schiavone S, Tucci P, et al. The NADPH oxidase NOX2 controls glutamate release: A novel mechanism involved in psychosis-like ketamine responses. J Neurosci. 2010 ; 30: 11317-11325
229. Stahl S Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge, UK: Cambridge University Press ; 2013:
230. Stokes PRA, Shotbolt P, Mehta MA, et al. Nature or nurture? Determining the heritability of human striatal dopamine function: An [18F]-DOPA PET study. Neuropsychopharmacology. 2013 ; 38: 485-491
231. Stone JM. Glutamatergic antipsychotic drugs: A new dawn in the treatment of schizophrenia?. Ther Adv Psychopharmacol. 2011 ; 1: 5-18
232. Stone JM, Day F, Tsagaraki H, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to gray matter volume. Biol Psychiatry. 2009 ; 66: 533-539
233. Stone JM, Howes OD, Egerton A, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry. 2010 ; 68: 599-602
234. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. J Psychopharmacol. 2007 ; 21: 440-452
235. Stone JM, Pepper F, Fam J, et al. Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology (Berl). 2014 ; 231: 2107-2116
236. Suridjan I, Rusjan P, Addington J, et al. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci. 2013 ; 38: 98-106
237. Szulc A, Konarzewska B, Galinska-Skok B, et al. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci Lett. 2013 ; 547: 37-41
238. Tamminga CA, Holcomb HH, Gao XM, et al. Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions. Int Clin Psychopharmacol. 1995 ; 10: 29-37
239. Tandon N, Bolo NR, Sanghavi K, et al. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res. 2013 ; 148: 59-66
240. Tayoshi S, Sumitani S, Taniguchi K, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009 ; 108: 69-77
241. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003 ; 160: 2231-2233
242. Théberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002 ; 159: 1944-1946
243. Thompson JL, Urban N, Slifstein M, et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry. 2013 ; 18: 909-915
244. Tibbo P, Hanstock C, Valiakalayil A, et al. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry. 2004 ; 161: 1116-1118
245. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005 ; 66: 1012-1015
246. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2009 ; 109: 10-14
247. Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010 ; 16: 522-537
248. Tsukada H, Harada N, Nishiyama S, et al. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse. 2000 ; 37: 95-103
249. Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014 ;:
250. Vernaleken I, Klomp M, Moeller O, et al. Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol. 2013 ; 16: 745-754
251. Videbaek C, Toska K, Scheideler MA, et al. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse. 2000 ; 38: 338-342
252. Volk S, Maul FD, Hör G, et al. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia. Psychiatry Res. 1994 ; 55: 111-118
253. Vollenweider FX, Vontobel P, Oye I, et al. Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res. 2000 ; 34: 35-43
254. Walinder J, Skott A. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique. Arch Gen Psychiatry. 1976 ; 33: 501-505
255. Wang M, Pei L, Fletcher PJ, et al. Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: Increased dopamine D2 receptor dimerization. Mol Brain. 2010 ; 3: 25
256. Ward RD, Simpson EH, Richards VL, et al. Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia. Neuropsychopharmacology. 2012 ; 37: 1699-1707
257. Weinberger D. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987 ; 45: 1055
258. Weiser M, Heresco-Levy U, Davidson M, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 ; 73: e728 - e734
259. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet. 2013 ; 382: 1575-1586
260. Winton-Brown T, Fusar-Poli P, Ungless M, et al. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 2014 ; 37: 85-94
261. Wolkin A. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry. 1989 ; 46: 482
262. Yoo SY, Yeon S, Choi C-H, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res. 2009 ; 111: 86-93
263. Zhang L, Shirayama Y, Iyo M, et al. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007 ; 32: 2004-2010
264. Zwanzger P, Zavorotnyy M, Gencheva E, et al. Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide - a 3T-MRS study in healthy subjects. Neuropsychopharmacology. 2013 ; 38: 1648-1654